Post-translational modifications of ezrin: a crucial regulator for diseases
Amino Acids · 2025
DOI: 10.1007/s00726-025-03472-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Amino Acids, 2025. Verfasst von Yi-Chen Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Protein Processing, Post-Translational, Cytoskeletal Proteins, Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Shanghai Education Development Foundation and Shanghai Municipal Education Commission.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. collegeylm@shutcm.edu.cn.
- Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. collegeylm@shutcm.edu.cn.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Shanghai Education Development Foundation and Shanghai Municipal Education Commission
Zitieren
APA
Li, Y. C., Yuan, H. K., & Yin, L. M. (2025). Post-translational modifications of ezrin: a crucial regulator for diseases. Amino Acids. https://doi.org/10.1007/s00726-025-03472-3
Vancouver
Li YC, Yuan HK, Yin LM. Post-translational modifications of ezrin: a crucial regulator for diseases. Amino Acids. 2025. doi:10.1007/s00726-025-03472-3
BibTeX
@article{Li2025,
author = {Li, Yi-Chen and Yuan, Hong-Kai and Yin, Lei-Miao},
title = {Post-translational modifications of ezrin: a crucial regulator for diseases},
journal = {Amino Acids},
year = {2025},
doi = {10.1007/s00726-025-03472-3}
}
EUVIMED